169 related articles for article (PubMed ID: 34555647)
1. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.
Faron M; Cheugoua-Zanetsie AM; Thirion P; Nankivell M; Winter K; Cunningham D; Van der Gaast A; Law S; Langley R; de Vathaire F; Valmasoni M; Mauer M; Roth J; Gebski V; Burmeister BH; Paoletti X; van Sandick J; Fu J; Ducreux M; Blanchard P; Tierney J; Pignon JP; Michiels S;
Eur J Cancer; 2021 Nov; 157():278-290. PubMed ID: 34555647
[TBL] [Abstract][Full Text] [Related]
2. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
[TBL] [Abstract][Full Text] [Related]
3. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
[TBL] [Abstract][Full Text] [Related]
5. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
Faron M; Cheugoua-Zanetsie M; Tierney J; Thirion P; Nankivell M; Winter K; Yang H; Shapiro J; Vernerey D; Smithers BM; Walsh T; Piessen G; Nilsson M; Boonstra J; Ychou M; Law S; Cunningham D; de Vathaire F; Stahl M; Urba S; Valmasoni M; Williaume D; Thomas J; Lordick F; Tepper J; Roth J; Gebski V; Burmeister B; Paoletti X; van Sandick J; Fu J; Pignon JP; Ducreux M; Michiels S;
J Clin Oncol; 2023 Oct; 41(28):4535-4547. PubMed ID: 37467395
[TBL] [Abstract][Full Text] [Related]
6. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
7. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
[TBL] [Abstract][Full Text] [Related]
8. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
9. Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.
Vincent J; Mariette C; Pezet D; Huet E; Bonnetain F; Bouché O; Conroy T; Roullet B; Seitz JF; Herr JP; Di Fiore F; Jouve JL; Bedenne L;
Eur J Cancer; 2015 Sep; 51(13):1683-93. PubMed ID: 26163097
[TBL] [Abstract][Full Text] [Related]
10. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]).
Yoon HH; Ou FS; Soori GS; Shi Q; Wigle DA; Sticca RP; Miller RC; Leenstra JL; Peller PJ; Ginos B; Heying E; Wu TT; Drevyanko TF; Ko S; Mattar BI; Nikcevich DA; Behrens RJ; Khalil MF; Kim GP; Alberts SR
Eur J Cancer; 2021 Jun; 150():214-223. PubMed ID: 33934058
[TBL] [Abstract][Full Text] [Related]
11. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
[TBL] [Abstract][Full Text] [Related]
13. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
14. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
[TBL] [Abstract][Full Text] [Related]
15. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
[TBL] [Abstract][Full Text] [Related]
16. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
17. Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.
Jestin Hannan C; Linder G; Kung CH; Johansson J; Lindblad M; Hedberg J
Br J Surg; 2020 Oct; 107(11):1500-1509. PubMed ID: 32484241
[TBL] [Abstract][Full Text] [Related]
18. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.
Bystricky B; Okines AF; Cunningham D
Drugs; 2011 Mar; 71(5):541-55. PubMed ID: 21443280
[TBL] [Abstract][Full Text] [Related]
19. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
20. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
